 Dose-Response Relationship, Drug
"Dose-Response Relationship, Drug" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The relationship between the dose of an administered drug and the response of the organism to the drug.
| Descriptor ID |
D004305
|
| MeSH Number(s) |
G07.690.220
|
| Concept/Terms |
Dose-Response Relationship, Drug- Dose-Response Relationship, Drug
- Dose-Response Relationships, Drug
- Drug Dose-Response Relationship
- Drug Dose-Response Relationships
- Relationship, Drug Dose-Response
- Relationships, Drug Dose-Response
- Dose Response Relationship, Drug
|
Below are MeSH descriptors whose meaning is more general than "Dose-Response Relationship, Drug".
Below are MeSH descriptors whose meaning is more specific than "Dose-Response Relationship, Drug".
This graph shows the total number of publications written about "Dose-Response Relationship, Drug" by people in this website by year, and whether "Dose-Response Relationship, Drug" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1980 | 0 | 6 | 6 | | 1981 | 0 | 5 | 5 | | 1982 | 0 | 8 | 8 | | 1983 | 0 | 7 | 7 | | 1984 | 0 | 4 | 4 | | 1985 | 0 | 8 | 8 | | 1986 | 0 | 6 | 6 | | 1987 | 0 | 12 | 12 | | 1988 | 0 | 11 | 11 | | 1989 | 0 | 16 | 16 | | 1990 | 0 | 23 | 23 | | 1991 | 0 | 25 | 25 | | 1992 | 0 | 28 | 28 | | 1993 | 0 | 39 | 39 | | 1994 | 0 | 28 | 28 | | 1995 | 0 | 29 | 29 | | 1996 | 0 | 22 | 22 | | 1997 | 0 | 28 | 28 | | 1998 | 0 | 32 | 32 | | 1999 | 0 | 34 | 34 | | 2000 | 0 | 46 | 46 | | 2001 | 0 | 53 | 53 | | 2002 | 0 | 70 | 70 | | 2003 | 1 | 72 | 73 | | 2004 | 0 | 71 | 71 | | 2005 | 0 | 67 | 67 | | 2006 | 0 | 66 | 66 | | 2007 | 1 | 57 | 58 | | 2008 | 1 | 67 | 68 | | 2009 | 1 | 50 | 51 | | 2010 | 0 | 56 | 56 | | 2011 | 0 | 57 | 57 | | 2012 | 0 | 51 | 51 | | 2013 | 0 | 41 | 41 | | 2014 | 0 | 48 | 48 | | 2015 | 3 | 43 | 46 | | 2016 | 0 | 35 | 35 | | 2017 | 0 | 28 | 28 | | 2018 | 0 | 39 | 39 | | 2019 | 0 | 33 | 33 | | 2020 | 0 | 12 | 12 | | 2021 | 1 | 13 | 14 | | 2022 | 0 | 4 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Dose-Response Relationship, Drug" by people in Profiles.
-
LoRusso P, Ratain MJ, Doi T, Rasco DW, de Jonge MJA, Moreno V, Carneiro BA, Devriese LA, Petrich A, Modi D, Morgan-Lappe S, Nuthalapati S, Motwani M, Dunbar M, Glasgow J, Medeiros BC, Calvo E. Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study. Invest New Drugs. 2022 08; 40(4):762-772.
-
D'Haens GR, Sandborn WJ, Loftus EV, Hanauer SB, Schreiber S, Peyrin-Biroulet L, Panaccione R, Panés J, Baert F, Colombel JF, Ferrante M, Louis E, Armuzzi A, Zhou Q, Goteti VS, Mostafa NM, Doan TT, Petersson J, Finney-Hayward T, Song AP, Robinson AM, Danese S. Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results. Gastroenterology. 2022 06; 162(7):1876-1890.
-
Chen X, Schneewind O, Missiakas D. Engineered human antibodies for the opsonization and killing of Staphylococcus aureus. Proc Natl Acad Sci U S A. 2022 01 25; 119(4).
-
Buocikova V, Longhin EM, Pilalis E, Mastrokalou C, Miklikova S, Cihova M, Poturnayova A, Mackova K, Babelova A, Trnkova L, El Yamani N, Zheng C, Rios-Mondragon I, Labudova M, Csaderova L, Kuracinova KM, Makovicky P, Kucerova L, Matuskova M, Cimpan MR, Dusinska M, Babal P, Chatziioannou A, Gabelova A, Rundén-Pran E, Smolkova B. Decitabine potentiates efficacy of doxorubicin in a preclinical trastuzumab-resistant HER2-positive breast cancer models. Biomed Pharmacother. 2022 Mar; 147:112662.
-
Peer CJ, Heiss BL, Goldstein DA, Goodell JC, Figg WD, Ratain MJ. Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation. J Clin Pharmacol. 2022 04; 62(4):532-540.
-
Ratziu V, Rinella ME, Neuschwander-Tetri BA, Lawitz E, Denham D, Kayali Z, Sheikh A, Kowdley KV, Desta T, Elkhashab M, DeGrauw J, Goodwin B, Ahmad A, Adda N. EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. J Hepatol. 2022 03; 76(3):506-517.
-
Abburi C, McDaid J. Ethanol interaction with a3ß4 nicotinic acetylcholine receptors in neurons of the laterodorsal tegmentum. Alcohol Clin Exp Res. 2021 12; 45(12):2495-2505.
-
Connors JM, Brooks MM, Sciurba FC, Krishnan JA, Bledsoe JR, Kindzelski A, Baucom AL, Kirwan BA, Eng H, Martin D, Zaharris E, Everett B, Castro L, Shapiro NL, Lin JY, Hou PC, Pepine CJ, Handberg E, Haight DO, Wilson JW, Majercik S, Fu Z, Zhong Y, Venugopal V, Beach S, Wisniewski S, Ridker PM. Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial. JAMA. 2021 11 02; 326(17):1703-1712.
-
Ji Y, Yuan S. Practical Impact of Modern Dose-Finding Designs When Compared With the 3 + 3 Design: An Editorial. JCO Precis Oncol. 2021 11; 5:1584-1587.
-
Clarke WA, Chatelut E, Fotoohi AK, Larson RA, Martin JH, Mathijssen RHJ, Salamone SJ. Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy. Eur J Cancer. 2021 11; 157:428-440.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|